TESAM OPTA^New

                                                                                                                                                                                                                                

Contents	Vial: Tesamorelin, 2mg/vial × 5            Ampoule: 2ml Bacteriostatic Water
Description	TESAM OPTA is an advanced peptide formulation containing Tesamorelin, a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) designed to stimulate the pituitary gland and enhance endogenous growth hormone (GH) production.         It is clinically recognized for its ability to significantly reduce visceral adipose tissue (VAT), particularly in the abdominal region, making it highly effective for targeted fat loss and metabolic improvement. By increasing natural GH secretion, Tesamorelin supports improved body composition, enhanced lipid metabolism, and overall metabolic health.         TESAM OPTA is widely used in protocols focused on fat reduction, physique enhancement, and metabolic optimization, especially in individuals with excess abdominal fat or metabolic imbalance.
Administration	Subcutaneous (SC) injection.
Storage	Before reconstitution: Store at room temperature, away from heat and direct sunlight.            After reconstitution: Refrigerate between 2–8°C.
Dosage	Recommended: 2 mg once daily via subcutaneous injection. Administration is typically advised under medical supervision.         Half-life: ~30 minutes (with prolonged biological activity via GH stimulation).
Indication	TESAM OPTA is indicated for:                    Reduction of excess abdominal fat (visceral adipose tissue)            Support in metabolic disorders            Improvement of lipid profiles            Body composition management
Contraindications	Do not use TESAM OPTA if:                    Hypersensitivity to Tesamorelin or formulation components            Active malignancy            Pregnancy and lactation            Disruption of hypothalamic-pituitary axis            Known pituitary tumors or history of pituitary surgery
Special Precautions	Use with caution in diabetic patients; monitor blood glucose levels.            Evaluate IGF-1 levels periodically during treatment.            Discontinue therapy if tumor growth or adverse metabolic changes are observed.            Not recommended without medical supervision.
Adverse Drug Reactions	Common: Injection site reactions (redness, itching, pain)            Others: Joint pain, edema, muscle stiffness, headache            Metabolic: Increased blood glucose levels in some individuals
Drug Interactions	Caution is required when used with:                    Drugs affecting glucose metabolism (e.g., insulin, oral hypoglycemics)            Glucocorticoids – May alter GH response
Disclaimer	Images displayed on the website are for representational purposes only, which may differ from the actual purchased product. The company may change or alter the packaging design without notice.